Results 31 to 40 of about 12,771 (176)

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia

Brazilian Journal of Nephrology, 2020
Imatinib, which inhibits tyrosine kinase activity of Bcr-Abl protein, is a standard form of treatment for chronic myeloid leukemia (CML). Through its immunomodulatory effect it affects T cell function in a number of ways.
Abhilash Chandra, Namrata Rao, Kiran Preet Malhotra   +2 more
doaj   +2 more sources

Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells [PDF]

Cell Research, 2008
This study examined the signaling events induced by shikonin that lead to the induction of apoptosis in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells (e.g., K562, LAMA84). Treatment of K562 cells with shikonin (e.g., 0.5 muM) resulted in profound induction of apoptosis accompanied by rapid generation of reactive oxygen species (ROS ...
Xin, Mao, Chun Rong, Yu, Wen Hua, Li, Wen Xin, Li   +3 more
openaire   +2 more sources

ACUTE UNDIFFERENTIATED LEUKEMIA WITH BCR-ABL TRANSLOCATION: CASE REPORT AND LITERATURE REVIEW

Hematology, Transfusion and Cell Therapy, 2021
The 2016 WHO classification defines acute undifferentiated leukemia (AUL) as a rare type of acute leukemia (AL) without defining markers for either lymphoid or myeloid lineage commitment.
AC Cortez, AD Costa, VDA Bovolenta, MM Nascimento, J Schmidt-Filho, DRA Silveira   +5 more
doaj   +1 more source

A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia [PDF]

Blood Cancer Journal, 2014
Aurora kinase overexpression has been observed in patients with hematologic malignancies. MK-0457, a pan-aurora kinase inhibitor that also inhibits the ABL T315I mutant, was evaluated to treat patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome (Ph+) acute lymphoblastic leukemia (ALL) with the T315I mutation.
Seymour, J. F, Kim, D. W., Rubin, E., Haregewoin, A., Clark, J., Watson, P., Hughes, T., Dufva, I., Jimenez, J. L., Mahon, F. X., Rousselot, P., Cortes, J., MARTINELLI, GIOVANNI, PAPAYANNIDIS, CRISTINA, Nagler, A., Giles, F. J.   +15 more
openaire   +4 more sources

Priapism as the first manifestation in chronic myeloid leukemia: A case report and focused review of literature

Clinical Case Reports, 2021
We report the case of a patient who was initially presented with ischemic priapism to the emergency department. He was treated with adrenaline intracavernous injections and aspiration with irrigation of the corpora cavernosa and distal shunt.
Claudia Lucia Sossa Melo, Carlos Alberto Orozco Orozco, Angela Maria Peña Castellanos, Maria Alejandra Rueda Perea, Cristian Orlando Porras Bueno, Carlos Ivan Romero Diaz, Helga Natalia Rojas Rodríguez   +6 more
doaj   +1 more source

Does thyroid dysfunction happen in CML patients receiving Imatinib for treatment? [PDF]

Reviews in Clinical Medicine, 2015
Chronic myelogenous leukemia is a myeloproliferative disorder presenting with anemia, elevated blood granulocytosis and the presence of immature granulocytes, basophilia, frequently thrombocytosis and spleen enlargement.
Hossein Rahimi, Zahra Mazloum Khorasani, Saeedeh Shariati   +2 more
doaj   +3 more sources

Polycythemia vera masked due to severe iron deficiency anemia

Hematology/Oncology and Stem Cell Therapy, 2018
Polycythemia vera is one of the chronic myeloproliferative diseases and very few patients present with its actual clinical manifestations. The most common findings are increased red cell mass and an increased leukocyte count with decreased erythropoietin.
Shweta Kambali, Asma Taj
doaj   +1 more source

Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization

Annals of Oncology, 1999
In 5%-10% of patients with of chronic myelogenous leukemia (CML), the Philadelphia chromosome (Ph) is not identified, despite the presence of the associated BCR-ABL molecular abnormality (Ph-negative, BCR-ABL-positive CML) because of sub-microscopic rearrangements.Six patients with Ph-negative, BCR-ABL-positive CML were investigated.
D, Seong, H M, Kantarjian, M, Albitar, R, Arlinghaus, J, Xu, M, Talpaz, M B, Rios, J Q, Guo, S, O'Brien, M, Siciliano   +9 more
openaire   +2 more sources

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells [PDF]

Leukemia, 2001
The ABL-specific tyrosine kinase inhibitor STI571 (formerly CGP57148B) induced cytogenetic remissions in 33% of chronic myelogenous leukemia (CML) patients in a phase I trial (Druker et al 1999). Combination therapy may increase this proportion. We tested whether combinations of STI571 and cytarabine or other chemotherapeutic agents such as hydroxyurea,
J, Topaly, W J, Zeller, S, Fruehauf
openaire   +2 more sources

Chronic myelogenous leukemia presenting with Morel Lavallée lesion: A case report of a rare presentation

Clinical Case Reports, 2022
Chronic myelogenous leukemia is a myeloproliferative neoplasm characterized by the BCR‐ABL1 fusion gene and the development of the Philadelphia chromosome, which leads to an increase in granulocytes and bone marrow myeloid precursors in the blood, it can
Sara S. I. Mohamed, Hana Mahmoud Qasim, Ahmed Mahfouz, Maab A. Osman, Ashraf O. E. Ahmed, Safa H. Al‐Azewi, Mohamad A. Yassin, Shehab Fareed   +7 more
doaj   +1 more source